Storia in 3 fonti

Neumora depression drug fails; EnGene to cut 50% of staff

Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

Raccontata da

endpoints.news

benzinga.com

biopharmadive.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

Neumora depression drug fails; EnGene to cut 50% of staff

originale

endpoints.news1 mese fa

Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.

Leggi questa versione → originale

Timeline cronologica

lunedì 15 giugno 2026·endpoints.news
Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff
Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.
lunedì 15 giugno 2026·benzinga.com
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.

Neumora depression drug fails; EnGene to cut 50% of staff

Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Timeline cronologica

Neumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD

Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Neumora Therapeutics (NASD

Neumora depression drug fails; EnGene to cut 50% of staff